During the past decade, Cedar-Crosse Research Center conducted 30 clinical trials. In the 10-year time frame, 30 clinical trials started and 32 clinical trials were completed, i.e. on average, 106.7% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 14 clinical trials were completed. i.e. 107.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Cedar-Crosse Research Center" #1 sponsor was "AstraZeneca" with 11 trials, followed by "Boehringer Ingelheim" with 7 trials sponsored, "Eli Lilly and Company" with 6 trials sponsored, "Pfizer" with 6 trials sponsored and "Mannkind Corporation" with 6 trials sponsored. Other sponsors include 22 different institutions and companies that sponsored additional 26 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Cedar-Crosse Research Center" #1 collaborator was "Bristol-Myers Squibb" with 4 trials as a collaborator, "Eli Lilly and Company" with 4 trials as a collaborator, "Alder Biopharmaceuticals, Inc." with 1 trials as a collaborator, "Astra Zeneca, Bristol-Myers Squibb" with 1 trials as a collaborator and "Medical Research Council Population Health Research Unit, CTSU, University of Oxford (academic lead)" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Cedar-Crosse Research Center" are "Diabetes Mellitus, Type 2" (12 trials), "Type 2 Diabetes Mellitus" (10 trials), "Type 2 Diabetes" (9 trials), "Hypertension" (8 trials) and "Migraine" (5 trials). Many other conditions were trialed in "Cedar-Crosse Research Center" in a lesser frequency.

Most popular intervention types in "Cedar-Crosse Research Center" are "Drug" (58 trials), "Biological" (4 trials), "Behavioral" (3 trials), "Other" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (26 trials), "Dapagliflozin" (7 trials), "Metformin" (6 trials), "Saxagliptin" (5 trials) and "Metformin XR" (4 trials). Other intervention names were less common.

The vast majority of trials in "Cedar-Crosse Research Center" are 62 trials for "All" genders.

Currently, there are NaN active trials in "Cedar-Crosse Research Center". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 47 completed trials in Cedar-Crosse Research Center, 2 suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Cedar-Crosse Research Center, 1 "Phase 1" clinical trials were conducted, 22 "Phase 2" clinical trials and 34 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 0 trials that are defined as “Not Applicable".